Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

被引：0
|
作者：
Broeckelmann, Paul J. [1 ]
Buehnen, Ina [1 ]
Herhaus, Peter [2 ]
Meissner, Julia [3 ]
Trautmann-Grill, Karolin [4 ]
Mueller, Horst [1 ]
Fuchs, Michael [1 ]
von Tresckow, Bastian [5 ]
Borchmann, Peter [1 ]
Engert, Andreas [1 ]
Behringer, Karolin [1 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med, German Hodgkin Study Grp GHSG, Cologne, Germany
[2] Tech Univ Munich, Sch Med, Clin & Policlin Internal Med 3, Klinikum Rechts Isar, Munich, Germany
[3] Univ Hosp Heidelberg, Med 5, Heidelberg, Germany
[4] Univ Hosp Carl Gustav Carus, Med Clin 1, Dresden, Germany
[5] West German Canc Ctr Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189250
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer
    Luo, Hui-yan
    Xu, Rui-hua
    Wang, Feng
    Qiu, Miao-zhen
    Li, Yu-hong
    Li, Fang-hua
    Zhou, Zhi-wei
    Chen, Xiao-qin
    CHEMOTHERAPY, 2010, 56 (02) : 94 - 100
  • [22] Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial
    Flinn, Ian W.
    Mainwaring, Mark
    Peacock, Nancy
    Shipley, Dianna
    Arrowsmith, Edward
    Savona, Michael R.
    Hainsworth, John D.
    Berdeja, Jesus G.
    BLOOD, 2012, 120 (21)
  • [23] PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup
    Fornecker, Luc-Matthieu
    Lazarovici, Julien
    Aurer, Igor
    Casasnovas, Rene-Olivier
    Gac, Anne-Claire
    Bonnet, Christophe
    Bouabdallah, Krimo
    Perrot, Aurore
    Specht, Lena
    Touati, Mohamed
    Eisenmann, Jean Claude
    Borel, Cecile
    Stamatoullas, Aspasia
    Nicolas-Virelizier, Emmanuelle
    Pascal, Laurent
    Lugtenburg, Pieternella
    Bellei, Monica
    Traverse-Glehen, Alexandra
    Copie, Christiane
    Hutchings, Martin
    Versari, Annibale
    Meignan, Michel
    Federico, Massimo
    Andre, Marc
    BLOOD, 2017, 130
  • [24] ANALYSIS OF HODGKIN'S LYMPHOMA PATIENTS WITH INCOMPLETE METABOLIC RESPONSE AFTER FIRST-LINE SYSTEMIC THERAPY
    Liao, Donna
    Aminilari, Mahmood
    Tsao, May
    Ahmed, Sameera
    Ye, Xiang Y.
    Prica, Anca
    Metser, Ur
    Singnurkar, Amit
    Hodgson, David
    RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S4 - S4
  • [25] ANALYSIS OF HODGKIN'S LYMPHOMA PATIENTS WITH INCOMPLETE METABOLIC RESPONSE AFTER FIRST-LINE SYSTEMIC THERAPY
    不详
    RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S4 - S4
  • [26] Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
    Vasudev, N. S.
    Ainsworth, G.
    Brown, S.
    Pickering, L.
    Waddell, T. S.
    Fife, K.
    Griffiths, R.
    Sharma, A.
    Katona, E.
    Howard, H.
    Velikova, G.
    Maraveyas, A.
    Brown, J. E.
    Venugopal, B.
    Patel, P.
    Jain, A.
    Symeonides, S.
    Nathan, P. D.
    Collinson, F.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1304 - S1305
  • [27] Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial
    Hou, Zhenyu
    Zhu, Keyun
    Yang, Xuejiao
    Chen, Ping
    Zhang, Wei
    Cui, Yunlong
    Zhu, Xiaolin
    Song, Tianqiang
    Li, Qiang
    Li, Huikai
    Zhang, Ti
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (17)
  • [28] Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
    Eichenauer, Dennis A.
    Pluetschow, Annette
    Kreissl, Stefanie
    Soekler, Martin
    Hellmuth, Johannes C.
    Meissner, Julia
    Mathas, Stephan
    Topp, Max S.
    Behringer, Karolin
    Klapper, Wolfram
    Kuhnert, Georg
    Dietlein, Markus
    Kobe, Carsten
    Fuchs, Michael
    Diehl, Volker
    Engert, Andreas
    Borchmann, Peter
    LANCET ONCOLOGY, 2017, 18 (12): : 1680 - 1687
  • [29] Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
    Martinez, Carmen
    Rodriguez-Calvillo, Mercedes
    Terol, Maria Jose
    Xicoy, Blanca
    Garcia-Sanz, Ramon
    Perez-Ceballos, Elena
    Cantalapiedra, Alberto
    Domingo-Domenech, Eva
    Hernandez, Miguel
    Sampol, Antonia
    Espeso, Manuel
    Briones, Javier
    Lopez, Javier
    Sureda, Anna
    BLOOD, 2012, 120 (21)
  • [30] First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: Phase II trial
    Hainsworth, JD
    Litchy, S
    Lamb, MR
    Rodriguez, GI
    Scroggin, C
    Greco, FA
    CLINICAL LYMPHOMA, 2003, 4 (01): : 36 - 42
12345